Literature DB >> 10701820

Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells.

N Fukuda1, W Y Hu, A Kubo, H Kishioka, C Satoh, M Soma, Y Izumi, K Kanmatsuse.   

Abstract

Angiotensin II (Ang II) and transforming growth factor-beta (TGF-beta) modulate cell growth and metabolism. Our objective was to evaluate the effect of Ang II on the characteristics and expression of TGF-beta receptors on vascular smooth muscle cells (VSMC) from Wistar-Kyoto rats. The addition of TGF-beta1 elicited a biphasic response on DNA synthesis in cultured VSMC in the absence of Ang II, but TGF-beta1 did not stimulate DNA synthesis in the presence of Ang II. TGF-beta binding data showed that Ang II increased the specific binding of 125I-TGF-beta1 by enhancing the expression of lower affinity receptors and increasing the number of binding sites. Ang II alone did not stimulate DNA synthesis in these cultures. However, Ang II significantly stimulated DNA synthesis after the inhibition of endogenous TGF-beta with a neutralizing antibody. The DNA synthesis stimulated by phorbol ester milisterol (PMA) was not affected by the TGF-beta neutralizing antibody. Affinity labeling data revealed receptor-ligand complexes of 280, 85, and 70 kDa, corresponding to TGF-beta type III, II, and I receptors, respectively. Incubation of VSMC with Ang II but not with PMA markedly increased the expression of the TGF-beta type I receptor. Reverse transcription and polymerase chain reaction data also indicated that Ang II, but not PMA, significantly increased the expression of TGF-beta type I receptor mRNA. Results suggest that Ang II increases the binding of TGF-beta with upregulation of TGF-beta type I receptor via a C-kinase-independent pathway. The enhanced expression of the TGF-beta type I receptor may counteract Ang II-promoted growth of VSMC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10701820     DOI: 10.1016/s0895-7061(99)00152-1

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  22 in total

1.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

Review 2.  TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

Authors:  Elena Gallo MacFarlane; Julia Haupt; Harry C Dietz; Eileen M Shore
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

3.  AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney.

Authors:  Hyung Eun Yim; Mee Kyung Kim; In Sun Bae; Ji Hae Kim; Byung Min Choi; Kee Hwan Yoo; Young Sook Hong; Joo Won Lee
Journal:  Pediatr Nephrol       Date:  2006-08-01       Impact factor: 3.714

4.  Editorial Commentary: Understanding Marfan syndrome, or "how not to invent the light bulb".

Authors:  Jeffrey A Jones
Journal:  Trends Cardiovasc Med       Date:  2016-02-23       Impact factor: 6.677

5.  Atenolol versus losartan in children and young adults with Marfan's syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lynn A Sleeper; Anji T Yetman; Timothy J Bradley; Steven D Colan; Gail D Pearson; E Seda Selamet Tierney; Jami C Levine; Andrew M Atz; D Woodrow Benson; Alan C Braverman; Shan Chen; Julie De Backer; Bruce D Gelb; Paul D Grossfeld; Gloria L Klein; Wyman W Lai; Aimee Liou; Bart L Loeys; Larry W Markham; Aaron K Olson; Stephen M Paridon; Victoria L Pemberton; Mary Ella Pierpont; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; Angela M Sharkey; Mario P Stylianou; Stephanie Burns Wechsler; Luciana T Young; Lynn Mahony
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

6.  Deletion of NF-κB/RelA in Angiotensin II-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation.

Authors:  Talha Ijaz; Hong Sun; Irina V Pinchuk; Dianna M Milewicz; Ronald G Tilton; Allan R Brasier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-17       Impact factor: 8.311

7.  A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease.

Authors:  Dongyan Liu; Connie J Wang; Daniel P Judge; Marc K Halushka; Jie Ni; Jennifer P Habashi; Javid Moslehi; Djahida Bedja; Kathleen L Gabrielson; Hangxue Xu; Feng Qian; David Huso; Harry C Dietz; Gregory G Germino; Terry Watnick
Journal:  J Am Soc Nephrol       Date:  2013-09-26       Impact factor: 10.121

8.  Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Authors:  Jennifer P Habashi; Daniel P Judge; Tammy M Holm; Ronald D Cohn; Bart L Loeys; Timothy K Cooper; Loretha Myers; Erin C Klein; Guosheng Liu; Carla Calvi; Megan Podowski; Enid R Neptune; Marc K Halushka; Djahida Bedja; Kathleen Gabrielson; Daniel B Rifkin; Luca Carta; Francesco Ramirez; David L Huso; Harry C Dietz
Journal:  Science       Date:  2006-04-07       Impact factor: 47.728

Review 9.  Myofibroblasts and Fibrosis: Mitochondrial and Metabolic Control of Cellular Differentiation.

Authors:  Andrew A Gibb; Michael P Lazaropoulos; John W Elrod
Journal:  Circ Res       Date:  2020-07-16       Impact factor: 17.367

10.  Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?

Authors:  Xiang Wang; Ana-Maria Bosonea; Jeffrey Odenbach; Carlos Fernandez-Patron
Journal:  Curr Hypertens Rev       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.